The correlation between EGFR mutation status and DNA content of lung adenocarcinoma cells in pleural effusion

1Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Objectives: Lung adenocarcinomas with or without epidermal growth factor receptor (EGFR) mutations have shown different drug effects against EGFR inhibitors. But it is not very clear if EGFR mutation status affects the biological behavior of lung adenocarcinoma, because tumor gene regulation is very complicated and can be affected by many factors. We aimed to explore if EGFR mutation status is related with tumor malignant degree by investigating the relevance of EGFR mutation status with DNA content and aneuploid peaks of lung adenocarcinoma cells in pleural fluids without using EGFR-TKIs. Materials and Methods: 591 cases of lung adenocarcinoma patients in Hebei Tumor Hospital who had undergone EGFR gene detection and DNA quantitative analysis were collected from January 2012 to August 2018.They were divided into two groups: EGFR mutant group and non-mutant group. EGFR mutations were detected by Amplification Refractory Mutation System (ARMS) and ABI 7500 Fluorescence quantitative PCR with pleural effusions. DNA content and aneuploid peaks were detected by LD DNA image cytometry (DNA-ICM). Rank-sum test of SPSS 16 was used for statistical analysis. Results: The maximum DI, the mean DI of the first 20 cells greater than 5C, the percentage of cells greater than 5C and the number of cells greater than 9C of the first 20 cells in the mutant group were all higher than those in the non-mutant group, having statistical significance (p<0.001); the peaks of aneuploid cells in the mutant group occurred more often than those in the non-mutant group, having statistical significance (p<0.001). Conclusions: Our study has shown that advanced lung adenocarcinomas with EGFR-mutations had higher DI values, more aneuploid cells and more frequent aneuploid peaks compared with those without EGFR-mutations, suggesting that advanced lung adenocarcinomas with EGFR mutations are more aggressive than those without EGFR mutations.

References Powered by Scopus

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

7620Citations
N/AReaders
Get full text

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

4939Citations
N/AReaders
Get full text

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

3844Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic

14Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Du, Y., Guo, X., Wang, R., Ma, Y., Zhang, Y., Liu, Y., … Wang, H. (2020). The correlation between EGFR mutation status and DNA content of lung adenocarcinoma cells in pleural effusion. Journal of Cancer, 11(8), 2265–2272. https://doi.org/10.7150/jca.38615

Readers over time

‘20‘21‘2200.751.52.253

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

40%

Professor / Associate Prof. 1

20%

Lecturer / Post doc 1

20%

Researcher 1

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

83%

Immunology and Microbiology 1

17%

Save time finding and organizing research with Mendeley

Sign up for free
0